Skip to main content
Atencion Primaria logoLink to Atencion Primaria
. 2013 Apr 3;33(3):149–153. [Article in Spanish] doi: 10.1016/S0212-6567(04)79376-2

Proyecto EVAN-65: evaluación de la efectividad de la vacuna antineumocócica en mayores de 65 años

Evan-65 project: evaluation of the effectiveness of pneumococcus vaccination in the over-65s

A Vila Córcoles 1,*, O Ochoa Gondar 1, I Hospital Guardiola 1, X Bria Ferre 1, C Llor Vila 1, D Montañes Boncompte 1; Grupo De Estudio Evan-651
PMCID: PMC7675946  PMID: 14987499

Abstract

Objective

To assess the effectiveness of systematic pneumococcus vaccination (PV) in the over-65s by comparing rates of incidence and severity of the cases of pneumonia caught in the community (PCC), in two cohorts-those vaccinated (VC) and those not (NVC).

Design

Multi-centre study of cohorts.

Setting

Primary Health Care.

Participants

All those over 65 registered at 8 urban Health Districts and distributed into a VC (with PV) and an NVC.

Interventions

Active monitoring will be conducted for 3 years, with detection of all the PCC occurring during this period. Data sources will be the specific register of the PV programme and exhaustive review of primary Care and referral hospital clinical records (records of pneumonia cases admitted and records of pneumonia cases detected in Casualty).

Main measurement

Variables considered will be: age, sex, and presence or otherwise of risk factors linked to greater susceptibility to catching pneumonia (diabetes mellitus, low immunity levels, cardiopathy, COPD, tobacco dependency, alcoholism, splenectomy). To measure the effect, we will calculate the annual and overall accumulated (over 3 years) rates of incidence of pneumonia, as well as the relative and attributable risks. As measurements of its severity, we will analyse the mortality index and the “fine” ordinal scale of severity.

Discussion

The study will give a reply in terms of effectiveness and efficiency of the vaccine and will contribute to a definitive decision on the controversial question of the systematic indication of this vaccine for the over-65 population.

Key-words: Pneumococcus vaccination, Pneumonia caught in the community, Effectiveness

Footnotes

Estudio financiado con una Beca del Fondo de Investigaciones Sanitarias (expediente Beca FIS PI- 021117)

Bibliografía

  • 1.Subdirección General de Prestaciones y Evaluación de Tecnologías. Med Clin (Barc) 1994;10:383–386. [PubMed] [Google Scholar]
  • 2.Gil de Gómez Barragán M.J., Acítores Augusto J.M. Vacuna antineumocócica: ¿a quién hay que vacunar? Fmc. 1996;3:185–190. [Google Scholar]
  • 3.Pahissa Berga A. Vacunación antineumocócica. Tema pendiente de nuestra sanidad. Med Clin (Barc) 1991;13:499–501. [PubMed] [Google Scholar]
  • 4.Departament de Sanitat i Seguretat Social. Bulletí. Epidemiològic de Catalunya. 1995;16:102–110. [Google Scholar]
  • 5.Doyma; Barcelona: 1993. (Departament de Sanitat i Seguretat Social. Generalitat de Catalunya.Llibre Blanc: bases per a la integració de la prevenció a la pràctica assistencial). [Google Scholar]
  • 6.Álvarez M.J., Mayer M.A. El dilema sobre el coste efectividad de la vacuna antineumocócica sigue abierto. Medifam. 2001;3:115–121. [Google Scholar]
  • 7.Salleras L. Vacunación antineumocócica en la tercera edad. Vacunas Invest Pract. 2000;1:55–58. [Google Scholar]
  • 8.Plans P. Coste-efectividad de la vacunación antineumocócica 23-valente en Cataluña. Gac Sanit. 2002;16:392–400. doi: 10.1016/s0213-9111(02)71948-1. [DOI] [PubMed] [Google Scholar]
  • 9.Dorca J., Bello S., Blanquer J., De Celis P., Molinos L., Torres M. Diagnóstico y tratamiento de la neumonía adquirida en la comunidad. Arch Bronconeumol. 1997;33:240–246. doi: 10.1016/s0300-2896(15)30614-1. [DOI] [PubMed] [Google Scholar]
  • 10.Niederman M.S., Mandell L.A., Anzueto A., Bass J.E., Broghton W.A., Campbell G.D. Guidelines for the management of adults with community-adquired pneumonia. Diagnosis, assessment of severety, antimicrobial therapy, and prevention. Am J Respir Crit Care Med. 2001;163:1730–1754. doi: 10.1164/ajrccm.163.7.at1010. [DOI] [PubMed] [Google Scholar]
  • 11.Center for Disease Control and Prevention. Recommendations of the Advisory Committee on Innunization Practices,the American Academy of Pediatrics, and the Americademy of Family Physicians: use of reminder an recall by vaccination providers to increase vaccinations rates. Mmwr. 1998;47:715–717. [PubMed] [Google Scholar]
  • 12.Centers for Disease Control and Prevention. Adult immunization programs in nontraditional settings: quality standards and guidance for program evaluation -a report of the National Vaccine Advisory Committee. Mmwr. 2000;49:1–14. [PubMed] [Google Scholar]
  • 13.Task Force on Community Preventive Service. Recommendations regarding interventions to improve vaccinations coverage in children, adolescents and adults. Am J Prev Med. 2000;18:92–140. [PubMed] [Google Scholar]
  • 14.Vila A., Ochoa O., Hospital I., Marín M.L., Guinea I., Álvarez M. Grupo de estudio EVAN-65. Efectividad de la vacuna antineumocócica en pacientes mayores de 65 años. Medifam. 2003;13:297–314. [Google Scholar]
  • 15.Moore R.A., Wiffen P.J., Lipsky B.A. Are the pneumococcal polysaccharide vaccines effective? Meta-analysis of the prospective trials. BMC Family Practice. 2000;1:1. doi: 10.1186/1471-2296-1-1. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 16.Puig Barberà J., Belenguer Barea A., Goterris Pinto M., Brines Benlliure M.J. Efectividad de la vacuna frente al neumococo en el anciano. Revisión sistemática y metaanálisis. Aten Primaria. 2002;30:269–283. doi: 10.1016/S0212-6567(02)79027-6. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 17.Aller A.I., Garjón F.J., Buisán M.J., Palacín J.C. ¿Está justificada la vacunación contra el neumococo en mayores de 65 años? Aten Primaria. 2002;7:433–437. doi: 10.1016/S0212-6567(02)70601-X. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 18.Bello Dondra S. Los antígenos urinarios en el diagnóstico de la neumonía adquirida en la comunidad. Arch Bronconeumol. 2001;37:87–93. Supl 4. [Google Scholar]
  • 19.Fine M.J., Auble T.E., Yealy D.M., Hanusa B.H., Weissfeld L.A., Singer D.E. A prediction rule to identify low-risk patients with community-adquired pneumonia. N Engl J Med. 1997;336:243–250. doi: 10.1056/NEJM199701233360402. [DOI] [PubMed] [Google Scholar]

Articles from Atencion Primaria are provided here courtesy of Elsevier

RESOURCES